Literature DB >> 25245885

Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.

Truls S Ingebrigtsen1, Jacob L Marott, Børge G Nordestgaard, Peter Lange, Jesper Hallas, Morten Dahl, Jørgen Vestbo.   

Abstract

OBJECTIVE: We tested the hypothesis that use of and adherence to maintenance medication is low among individuals in the general population who have chronic obstructive pulmonary disease (COPD) , even in cases of severe and very severe COPD. DESIGN AND PARTICIPANTS: We identified 5,812 individuals with COPD from the Copenhagen General Population Study, and classified them according to the Global Initiative for Obstructive Lung Disease (GOLD) airflow limitation grades 1-4. Dispensing of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, long-acting anti-cholinergics, or long-acting beta2-agonists was identified in a nationwide registry. Use of medication was defined as medication dispensed during a one-year period , and adherence was calculated from dosages available in one year. KEY
RESULTS: Use of fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists varied from 2 % to 61 % (p < 0.001, test for trend), long-acting anti-cholinergics varied from 0.4 % to 36 % (p < 0.001), and long-acting beta2-agonists varied from 0.3 % to 11 % (p < 0.001. Among utilizers of these medications, adherence varied from 29 % to 56 % (p < 0.001, test for trend) across GOLD 1-4 for fixed-dose combinations of inhaled corticosteroids with long-acting beta2-agonists, from 51 % to 68 % (p = 0.11) for long-acting anti-cholinergics, and from 25 to 62 % (p = 0.01) for long-acting beta2-agonists.
CONCLUSIONS: Use of and adherence to maintenance medication for COPD in the general population was associated with the severity of COPD as defined by GOLD, but even in severe and very severe COPD, use and adherence was low.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25245885      PMCID: PMC4284264          DOI: 10.1007/s11606-014-3029-0

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  24 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Characteristics of undertreatment in COPD in the general population.

Authors:  Truls S Ingebrigtsen; Jacob L Marott; Jørgen Vestbo; Jesper Hallas; Børge G Nordestgaard; Morten Dahl; Peter Lange
Journal:  Chest       Date:  2013-12       Impact factor: 9.410

3.  The Danish prescription registries.

Authors:  D Gaist; H T Sørensen; J Hallas
Journal:  Dan Med Bull       Date:  1997-09

4.  Socioeconomic status and prognosis of COPD in Denmark.

Authors:  Peter Lange; Jacob Louis Marott; Jørgen Vestbo; Truls Sylvan Ingebrigtsen; Børge Grønne Nordestgaard
Journal:  COPD       Date:  2014-02-25       Impact factor: 2.409

5.  Potential risk factors for medication non-adherence in patients with chronic obstructive pulmonary disease (COPD).

Authors:  Maher R Khdour; Ahmed F Hawwa; Joseph C Kidney; Bronagh M Smyth; James C McElnay
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

6.  Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care.

Authors:  Kylie Hill; Roger S Goldstein; Gordon H Guyatt; Maria Blouin; Wan C Tan; Lori L Davis; Diane M Heels-Ansdell; Marko Erak; Pauline J Bragaglia; Itamar E Tamari; Richard Hodder; Matthew B Stanbrook
Journal:  CMAJ       Date:  2010-04-06       Impact factor: 8.262

7.  Adherence to inhaled therapy, mortality and hospital admission in COPD.

Authors:  J Vestbo; J A Anderson; P M A Calverley; B Celli; G T Ferguson; C Jenkins; K Knobil; L R Willits; J C Yates; P W Jones
Journal:  Thorax       Date:  2009-08-23       Impact factor: 9.139

8.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Authors:  Mette Thomsen; Truls Sylvan Ingebrigtsen; Jacob Louis Marott; Morten Dahl; Peter Lange; Jørgen Vestbo; Børge G Nordestgaard
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

9.  Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.

Authors:  Chris M Kozma; Michael Dickson; Amy L Phillips; Dennis M Meletiche
Journal:  Patient Prefer Adherence       Date:  2013-06-12       Impact factor: 2.711

10.  Overtreatment of COPD with inhaled corticosteroids--implications for safety and costs: cross-sectional observational study.

Authors:  Patrick White; Hannah Thornton; Hilary Pinnock; Sofia Georgopoulou; Helen P Booth
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

View more
  29 in total

1.  Ethnic Differences in Persistence with COPD Medications: a Register-Based Study.

Authors:  Yusun Hu; Lourdes Cantarero-Arévalo; Anne Frølich; Ramune Jacobsen
Journal:  J Racial Ethn Health Disparities       Date:  2017-04-13

2.  Capsule commentary on Ingebrigsten et al., Low use and adherence to maintenance medication in chronic obstructive pulmonary disease in the general population.

Authors:  Theresa I Shireman
Journal:  J Gen Intern Med       Date:  2015-01       Impact factor: 5.128

3.  Adherence and healthcare utilization among older adults with COPD and depression.

Authors:  Jennifer S Albrecht; Bilal Khokhar; Ting-Ying Huang; Yu-Jung Wei; Ilene Harris; Patience Moyo; Peter Hur; Susan W Lehmann; Giora Netzer; Linda Simoni-Wastila
Journal:  Respir Med       Date:  2017-06-03       Impact factor: 3.415

4.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

5.  Geographical and sociodemographic differences in discontinuation of medication for Chronic Obstructive Pulmonary Disease - A Cross-Classified Multilevel Analysis of Individual Heterogeneity and Discriminatory Accuracy (MAIHDA).

Authors:  Kani Khalaf; Sten Axelsson Fisk; Ann Ekberg-Jansson; George Leckie; Raquel Perez-Vicente; Juan Merlo
Journal:  Clin Epidemiol       Date:  2020-07-20       Impact factor: 4.790

6.  Trends in non-receipt of recommended COPD medication.

Authors:  Michael Poon; Priscila Pequeno; Shawn D Aaron; Matthew B Stanbrook; Harvey H Wong; Peter Cram; Andrea S Gershon
Journal:  ERJ Open Res       Date:  2022-04-25

7.  Adherence to Maintenance Medications among Older Adults with Chronic Obstructive Pulmonary Disease. The Role of Depression.

Authors:  Jennifer S Albrecht; Yujin Park; Peter Hur; Ting-Ying Huang; Ilene Harris; Giora Netzer; Susan W Lehmann; Patricia Langenberg; Bilal Khokhar; Yu-Jung Wei; Patience Moyo; Linda Simoni-Wastila
Journal:  Ann Am Thorac Soc       Date:  2016-09

Review 8.  Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.

Authors:  Federico Lavorini; Claudia Mannini; Elisa Chellini; Giovanni A Fontana
Journal:  Drugs Aging       Date:  2016-07       Impact factor: 3.923

9.  Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan.

Authors:  Qingqing Xu; Sarah S Laxa; Omar Serna; Sujit S Sansgiry
Journal:  Am Health Drug Benefits       Date:  2020-02

10.  Factors Associated With Nonreceipt of Recommended COPD Medications: A Population Study.

Authors:  Andrea S Gershon; Priscila Pequeno; Amanda Alberga Machado; Shawn D Aaron; Tetyana Kendzerska; Jin Luo; Matthew B Stanbrook; Wan C Tan; Joan Porter; Teresa To
Journal:  Chest       Date:  2021-06-16       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.